Predicted to enable MAP kinase kinase activity and protein kinase binding activity. Involved in several processes, including cellular response to sorbitol; positive regulation of macromolecule metabolic process; and response to ischemia. Used to study retinal disease. Human ortholog(s) of this gene implicated in cervical cancer and restrictive cardiomyopathy. Orthologous to human MAP2K3 (mitogen-activated protein kinase kinase 3); PARTICIPATES IN p38 MAPK signaling pathway; Fc epsilon receptor mediated signaling pathway; interleukin-12 signaling pathway; INTERACTS WITH 1-naphthyl isothiocyanate; 2,3,7,8-tetrachlorodibenzodioxine; 2,6-dinitrotoluene.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MAP2K3 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAP2K3 protein] and Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAP2K3 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MAP2K3 mRNA
[Chelating Agents binds to Copper] which results in increased expression of MAP2K3 mRNA and [Disulfiram binds to Copper] which results in decreased expression of MAP2K3 mRNA
[Chelating Agents binds to Copper] which results in increased expression of MAP2K3 mRNA and [Disulfiram binds to Copper] which results in decreased expression of MAP2K3 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MAP2K3 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAP2K3 protein] and Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAP2K3 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MAP2K3 mRNA
[perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of MAP2K3 mRNA and [perfluorooctane sulfonic acid co-treated with Pectins] results in increased expression of MAP2K3 mRNA
Opposite effect of JAK2 on insulin-dependent activation of mitogen-activated protein kinases and Akt in muscle cells: possible target to ameliorate insulin resistance.
Nonparticipation of nuclear factor kappa B (NFkappaB) in the signaling cascade of c-Jun N-terminal kinase (JNK)- and p38 mitogen-activated protein kinase (p38MAPK)-dependent tumor necrosis factor alpha (TNFalpha) induction in lipopolysaccharide (LPS)-stimulated microglia.
